IDH2 and central nervous system cancer: Our data are supporting and extending recent reports on the use of ddPCR assays to detect mutations in glioma tissue samples, including IDH mutations [29, 48, 49], TERT promoter mutations [49, 50], H3-3A mutations [51], and BRAF duplication [8].